EMA fast-tracks Revolution Medicines' pancreatic cancer drug review
The European Medicines Agency (EMA) has initiated a phased review of Revolution Medicines' investigational drug, daraxonrasib, for pancreatic cancer to expedite its assessment before a full marketing authorization application. This decision is based on positive Phase 3 data from the RASolute 302 trial, which showed significant improvements in overall and progression-free survival. Concurrently, Revolution Medicines is nearing completion of its rolling NDA submission to the U.S. FDA under a fast-track pilot program, highlighting global efforts to bring this therapy to patients.
Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com
Revolution Medicines Inc. stock has reached an all-time high of $193.12, trading just 1% below its 52-week high, marking a significant 424.05% increase over the past year despite being deemed overvalued by InvestingPro. This surge follows positive Phase 1/2 clinical trial results for its drug zoldonrasib, leading to increased price targets from UBS, Mizuho, and Wedbush, and reflects strong investor confidence in the company's cancer research and drug development.
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Revolution Medicines (NASDAQ: RVMD) has seen its stock price surge by nearly 140% in 2026 due to promising late-stage clinical trial results for its cancer treatments, which target previously "undruggable" RAS proteins. The company's lead candidate, daraxonrasib, has shown significant improvement in survival rates for pancreatic cancer patients and is nearing regulatory review, with other candidates also progressing. While not yet revenue-generating and still incurring high R&D costs, its strong pipeline and unique approach to oncology make it an appealing, albeit risky, investment for growth-oriented investors.
Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative?
Revolution Medicines reported positive Phase 1/2 data for its oral RAS(ON) G12D inhibitor zoldonrasib in pancreatic cancer, showing high response rates and manageable safety in combination with other treatments. These results support ongoing and planned global Phase 3 trials, strengthening the company's RAS-focused investment narrative. However, the article notes that investors should be aware of the high R&D spending and concentration risk associated with focusing on a single target class.
Revolution Medicines: A $40 Billion Bet on a Cancer Breakthrough, But At What Price?
Revolution Medicines (NASDAQ: RVMD) has seen its market capitalization surge to $40.23 billion due to groundbreaking Phase 3 trial results for its lead cancer drug, daraxonrasib, which showed unprecedented efficacy in metastatic pancreatic cancer. Despite having no revenue and consistent unprofitability, the company maintains a strong financial position with $4 billion in cash, enabling it to advance its pipeline of RAS(ON) inhibitors. While analysts mostly have a "Buy" consensus, the high valuation and execution risks in commercializing its drugs warrant caution, especially given the competitive landscape for KRAS inhibitors.
Revolution Medicines, Inc. Warrant Financial Disclosures & SEC Filings
This page provides access to Revolution Medicines, Inc. (RVMDW) financial disclosures and SEC filings, including Forms 10-K, 10-Q, 8-K, and other key documents. The filings highlight significant company events such as study results for Daraxonrasib, quarterly earnings, and participation in various healthcare conferences, detailing advancements in their RAS(ON) inhibitor pipeline. This resource helps users evaluate the company's financial performance and operational updates.
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines, Inc. announced promising Phase 1/2 clinical data for zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer. The results, presented at the ESMO Gastrointestinal Cancers Congress 2026, show compelling efficacy and manageable safety profiles for zoldonrasib combined with chemotherapy in previously untreated patients, and with daraxonrasib in previously treated patients. These findings support ongoing and planned Phase 3 trials, marking a significant step in developing targeted therapies for RAS-addicted cancers.
Revolution Medicines Reports 82% Response Rate for Zoldonrasib in Metastatic Pancreatic Cancer
Revolution Medicines presented promising Phase 1/2 data for zoldonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC), showing an 82% objective response rate with zoldonrasib plus modified FOLFIRINOX in first-line treatment. The company is advancing two simultaneous Phase 3 trials, RASolute 305 and the planned RASolute 309, to evaluate zoldonrasib in different treatment regimens and lines for RAS G12D-mutated PDAC patients. The strong efficacy signals, especially in a disease with historically poor survival rates, suggest the potential to significantly impact the standard of care.
Revolution Medicines (RVMD) Reports Phase 1 2 Pancreatic Cancer Data That Sets Up Phase 3
Revolution Medicines (RVMD) has reported promising Phase 1/2 trial data for its RAS(ON) inhibitor combinations, zoldonrasib and daraxonrasib, in metastatic pancreatic cancer. The data showed strong antitumor activity and manageable safety, particularly in patients with RAS G12D mutation, positioning the company for pivotal Phase 3 trials in both first-line and previously treated settings. These results are significant given the current lack of approved targeted options for this mutation in pancreatic cancer.
Revolution Medicines sees large block trade worth $196.7 million
Revolution Medicines Inc. experienced a large block trade of 1.06 million shares, representing 0.5% of its float, valued at $196.7 million. The transaction took place at a 1.3% discount from the opening price. Despite a 0.9% decline on the day of the trade, the stock has gained 133% since the beginning of the year.
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines, Inc. announced positive Phase 1/2 clinical data for its investigational drug zoldonrasib in combination regimens for patients with RAS G12D metastatic pancreatic cancer. The data, presented at the ESMO Gastrointestinal Cancers Congress 2026, demonstrated compelling safety and antitumor activity for zoldonrasib both with standard chemotherapy in previously untreated patients and with daraxonrasib in previously treated patients. These results support two ongoing and planned Phase 3 pivotal trials for zoldonrasib-based regimens in this aggressive cancer.
Revolution Medicines reports zoldonrasib pancreatic cancer data
Revolution Medicines reported a high treatment response rate of up to 82% for its zoldonrasib combinations in patients with RAS G12D metastatic pancreatic cancer, causing company shares to rise. These Phase 1/2 data, presented at the ESMO GI 2026 Congress, support the initiation of pivotal Phase 3 clinical trials, RASolute 305 and RASolute 309. The treatments specifically target oncogenic variants to inhibit tumor growth.
Revolution Medicines reports trial results for pancreatic cancer drug
Revolution Medicines Inc. announced positive results from two Phase 1/2 clinical trials for zoldonrasib in combination regimens for RAS G12D metastatic pancreatic ductal adenocarcinoma. The trials showed promising objective response rates and progression-free survival, supporting ongoing and planned Phase 3 trials. Despite the stock's significant surge, InvestingPro analysis suggests the company may be overvalued, though analysts maintain positive ratings.
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines, Inc. announced positive Phase 1/2 clinical data for its investigational drug zoldonrasib in combination regimens for RAS G12D metastatic pancreatic cancer. The data, presented at the ESMO Gastrointestinal Cancers Congress 2026, demonstrated compelling safety and antitumor activity for zoldonrasib combined with standard chemotherapy in previously untreated patients and with daraxonrasib in previously treated patients. These findings support ongoing and planned Phase 3 trials aimed at addressing the significant unmet needs in this aggressive cancer type.
Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options
Revolution Medicines director Sushil Patel exercised stock options for 2,955 shares and sold 5,580 shares of RVMD common stock on June 29, 2026. The sales were part of a pre-arranged Rule 10b5-1 trading plan and were executed at weighted-average prices ranging from $182.93 to $192.64 per share. Following these transactions, Patel directly holds 27,236 common shares, including restricted stock units.
Revolution Medicines director Sushil Patel sells $1.05m in stock By Investing.com
Revolution Medicines director Sushil Patel sold $1.05 million worth of company stock through a pre-arranged trading plan, following the exercise of stock options. These sales occurred when the stock was trading near its 52-week high, with InvestingPro analysis suggesting the stock is currently overvalued. Patel still retains over 21,000 direct shares and 13,000 derivative shares after the transactions.
Form 4 Revolution Medicines Inc For: 1 July By Investing.com
This article announces the filing of Form 4 for Revolution Medicines Inc. on July 1st. It also provides a market overview with current values for various indices, commodities, and bonds, along with trending news and market movers. The primary content focuses on the Form 4 filing for Revolution Medicines Inc. (RVMD) on July 1st.
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMD
This article provides a brief financial update for Revolution Medicines, Inc. (NASDAQ: RVMD), focusing on its forward price-to-sales ratio. It indicates current trading information and highlights that the market is closed with no recent trades. The content is primarily a data point from TradingView with no further analysis or narrative.
Price to earnings forward of Revolution Medicines, Inc. – BMV:RVMD
This article provides the "Price to earnings forward" metric for Revolution Medicines, Inc. (BMV:RVMD). The content appears to be a financial data point from TradingView, indicating that the market for RVMD was closed with no trades recorded at the time of publication. The article focuses solely on this specific financial data point.
Enterprise value to revenue forward of Revolution Medicines, Inc. – MIL:1RVMD
This article presents the enterprise value to revenue forward of Revolution Medicines, Inc. (MIL:1RVMD), a company listed on Euronext Milan. The page displays that the market was closed with no trades. It provides financial data and other information related to the company's valuation.
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMD
This article focuses on the enterprise value to revenue forward metric for Revolution Medicines, Inc. (NASDAQ: RVMD). It appears to be a financial data point from TradingView, indicating a specific financial ratio for the company. The content itself doesn't offer analysis but rather sets up the presentation of this financial metric.
Standing Ovation for the Undruggable: How Revolution Medicines Changed the Story of Pancreatic Cancer – Exclusive Interview
Revolution Medicines achieved a monumental breakthrough in pancreatic cancer treatment with their drug daraxonrasib, which significantly extended patient survival and improved quality of life. The Phase III trial results, presented at the 2026 ASCO Annual Meeting, demonstrated a doubling of median overall survival for patients. This success challenges the long-held belief that RAS-driven cancers, particularly in pancreatic cancer, were "undruggable" and represents a rapid development timeline from first-in-human testing to positive Phase III results.
Standing Ovation for the Undruggable: How Revolution Medicines Changed the Story of Pancreatic Cancer – Exclusive Interview
Revolution Medicines has achieved a significant breakthrough in pancreatic cancer treatment with its drug daraxonrasib, which doubled the median overall survival in a Phase III trial. This drug successfully targets the previously "undruggable" RAS mutation, offering hope for a disease that has historically been resistant to drug development. The rapid development and positive patient-reported outcomes, alongside impressive survival data, mark a monumental shift in the therapeutic landscape for pancreatic cancer.
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMD
This article provides the "Price to book forward" for Revolution Medicines, Inc. (NASDAQ: RVMD). It appears to be a financial data snippet from TradingView, offering a specific valuation metric for the company. The content primarily lists the company's ticker, name, and the market it trades on.
8-Day Rally Sends Revolution Medicines Stock Up 23%
Revolution Medicines (RVMD) stock has experienced an 8-day winning streak, resulting in a cumulative gain of 23% and a market cap increase of $7.1 billion, now standing at $38 billion. The article highlights RVMD's significant outperformance compared to the S&P 500 across various periods. Despite this momentum, it also cautions about the risk of single-stock investing without thorough analysis and promotes the Trefis High Quality Portfolio as a benchmark-outperforming alternative.
Price to earnings forward of Revolution Medicines, Inc. – MIL:1RVMD
This article focuses on the price to earnings forward for Revolution Medicines, Inc., traded on Euronext Milan under the symbol 1RVMD. It appears to be a financial data page from TradingView, providing an overview of the company's financials for investors. The content is primarily a navigation and informational structure around this key financial metric.
Proposed sale of RVMD common shares reported (NASDAQ: RVMD)
Revolution Medicines, Inc. (RVMD) has filed a Form 144 notice, indicating proposed sales of common stock through Morgan Stanley Smith Barney LLC. The filing details the intended sale of 2,955 shares from an exercise of stock options with a sale date of June 29, 2026, and 2,625 Restricted Stock Units dating back to June 15, 2024. This form serves as a notification of intent to sell securities and does not confirm actual transactions.
Price to sales forward of Revolution Medicines, Inc. – MIL:1RVMD
This article provides a financial snippet for Revolution Medicines, Inc. (MIL:1RVMD), focusing on its forward price-to-sales ratio. It appears to be a stub or a data point from a financial platform, indicating market closure and no recent trades. The content is primarily a listing on TradingView, giving brief financial overview without detailed analysis.
Revolution Medicines Is Maintained at Buy by Needham
Needham has maintained its Buy rating for Revolution Medicines. The article provides information on the analyst firm's stance towards the company.
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – NASDAQ:RVMD
This article provides the enterprise value to EBITDA forward for Revolution Medicines, Inc. (NASDAQ: RVMD). It appears to be a financial data point from TradingView, indicating a key valuation metric for the pharmaceutical company. The content itself seems to be a data page with minimal text beyond the title.
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – TRADEGATE:42Z
The article focuses on the enterprise value to EBITDA forward ratio for Revolution Medicines, Inc. (TRADEGATE:42Z). It is presented on a financial data platform, likely TradingView, which provides an overview of the company's financial metrics. The content indicates that the market is currently closed with no trades.
“Maybe the Best Thing That Happened Is That Didn’t Work Out”: Alan Sandler on Daraxonrasib
Alan Sandler, Chief Development Officer at Revolution Medicines, discusses the rapid development of Daraxonrasib for pancreatic cancer. The drug's journey began after Revolution Medicines pivoted from antifungal research to oncology, specifically RAS-addicted cancers. Daraxonrasib quickly progressed from first-in-human testing in 2022 to a positive phase III trial in 2026, with early phase I results in pancreatic cancer showing consistent promise.
Insider Sell: Jack Anders Sells 20,000 Shares of Revolution Medi
Jack Anders, CFO of a Revolution Medicines Inc. branch, sold 20,000 shares of RVMD on June 24, 2026. This transaction follows a pattern of insider selling, with no insider buys and 46 insider sells over the past year. The stock is currently trading at $168.33, significantly overvalued compared to its GF Value of $0.44.
Revolution Medicines (RVMD) CFO trades 20K shares under 10b5-1 plan
Revolution Medicines (RVMD) Chief Financial Officer Anders Jack reported selling 20,000 shares of common stock at prices between $167 and $170 per share, executed under a Rule 10b5-1 trading plan. On the same date, June 24, 2026, he exercised stock options to acquire 20,000 shares at $18.56 per share. Following these transactions, Jack directly owns 123,269 shares of RVMD, which includes 51,388 restricted stock units.
How Launching a Pivotal RAS G12D Pancreatic Cancer Trial At Revolution Medicines (RVMD) Has Changed Its Investment Story
Revolution Medicines has initiated RASolute 305, a pivotal Phase 3 trial for its drug zoldonrasib in metastatic RAS G12D pancreatic cancer, which is a significant step as no approved therapies currently exist for this mutation. This trial is expected to reshape the company's investment narrative, emphasizing its efforts in this area and the potential for new oncology franchises. However, investors are cautioned about the company's substantial ongoing losses and cash burn before potential revenues from successful trials materialize.
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $188.57, Implies 11% Upside
The average 12-month price target for Revolution Medicines, Inc. (RVMD) stock has been raised to $188.57, up from $187.29, implying an 11% potential upside from its Jun. 24 closing price. This new target is based on estimates from 21 analysts, with individual forecasts ranging from $151 to $263 per share. The consensus rating for RVMD remains a "Buy" across 22 analysts.
Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer
Revolution Medicines' second RAS inhibitor, zoldonrasib, showed an 82% overall response rate in combination with chemotherapy for pancreatic cancer patients with the RAS-G12D mutation, according to Phase 1/2 data. This significantly improves upon chemotherapy alone, which typically yields a 30-40% response rate. The company has launched a Phase 3 study for zoldonrasib and is pursuing leadership in pancreatic ductal adenocarcinoma treatment, building on the success of its lead asset, daraxonrasib.
Revolution Medicines Opens RASolute 305 Trial of Zoldonrasib in RAS G12D Pancreatic Cancer
Revolution Medicines has initiated its RASolute 305 Phase 3 trial, testing zoldonrasib in combination with chemotherapy for previously untreated metastatic RAS G12D pancreatic ductal adenocarcinoma. This trial aims to address a significant unmet need for patients with the RAS G12D mutation, which lacks targeted therapies despite being prevalent in about 40% of such cases. The study's design focuses on G12D-confirmed patients and features dual primary endpoints of progression-free survival and overall survival, with an early interim analysis for PFS expected to guide its trajectory.
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines will present clinical data from its RAS(ON) pipeline at the 2026 ESMO Gastrointestinal Cancers Congress. The presentations will include results from Phase 1/2 trials evaluating zoldonrasib in combination regimens for metastatic RAS G12D pancreatic ductal adenocarcinoma, as well as updates on two Phase 3 trials for daraxonrasib. This highlights the company's progress in developing targeted therapies for RAS-addicted cancers.
Jack Anders (RVMD) files to sell 20,000 shares after option exercise
Jack Anders has filed a Rule 144 notice to sell 20,000 shares of Revolution Medicines, Inc. (RVMD) common stock, stemming from an exercise of stock options with a cash settlement. The filing also reveals a previous sale of 2,722 shares on June 16, 2026, for $424,956.46. This is categorized as a routine compliance filing for insider resale following an option exercise.
Enterprise value to EBIT forward of Revolution Medicines, Inc. – NASDAQ:RVMD
This article focuses on the enterprise value to EBIT forward for Revolution Medicines, Inc. (NASDAQ: RVMD). It appears to be a financial data point from TradingView, presented without additional detailed analysis within the provided content. The main purpose is to display this specific financial metric for the company.
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
Revolution Medicines has initiated patient treatment in RASolute 305, a Phase 3 clinical trial for zoldonrasib. This trial evaluates zoldonrasib in combination with chemotherapy as a first-line treatment for patients with metastatic RAS G12D pancreatic cancer. The company highlights the critical need for effective treatments in pancreatic cancer, especially given the prevalence and poor prognosis associated with RAS G12D mutations.
Revolution Medicines (RVMD) director granted RSUs and stock options in latest Form 4
Revolution Medicines director Elizabeth M. Anderson received a grant of 1,191 restricted stock units and a stock option for 3,127 shares with an exercise price of $162.99. The stock option vests on the earlier of June 18, 2027, or the next Annual Meeting, provided she remains a service provider. Following these awards, Anderson directly holds 9,406 common shares, with an additional 26,990 shares held indirectly through a trust.
Revolution Medicines (RVMD) director receives new stock and option grants
Revolution Medicines director Frank Clyburn was granted 1,191 shares of common stock and 3,127 stock options with an exercise price of $162.99. These equity awards increase his direct holdings to 10,929 shares, which also include 4,080 restricted stock units. The options are set to vest on the earlier of June 18, 2027, or before the next annual meeting, provided he remains a Service Provider.
Revolution Medicines (NASDAQ: RVMD) director receives stock and 3,127-share option grant
Revolution Medicines (NASDAQ: RVMD) director Sushil Patel received equity awards, including 1,191 shares of common stock (restricted stock units) and a stock option for 3,127 shares. The option has an exercise price of $162.99 per share and expires on June 18, 2036, vesting fully on the earlier of one year from grant or just before the next annual meeting, subject to continued service. Following these awards, Patel directly holds 24,281 common shares.
Revolution Medicines (RVMD) director receives new RSU and option grants
Revolution Medicines director Flavia Borellini received new equity awards, including 1,191 Restricted Stock Units and a stock option for 3,127 shares with an exercise price of $162.99. These awards increase her direct holdings to 26,215 common shares. The stock option vests fully on the earlier of June 18, 2027, or before the next Annual Meeting, provided she remains a service provider.
Revolution Medicines begins phase 3 trial for pancreatic cancer
Revolution Medicines has initiated a Phase 3 clinical trial (RASolute 305) for its drug zoldonrasib, combined with chemotherapy, as a first-line treatment for metastatic RAS G12D pancreatic cancer. The stock has seen a significant surge, reflecting investor confidence in the company's pipeline. Another drug, daraxonrasib, has also shown promising results in a separate Phase 3 trial for pancreatic cancer.
Revolution Medicines begins Phase 3 pancreatic cancer trial
Revolution Medicines has initiated a global Phase 3 trial (RASolute 305) for its oral drug zoldonrasib in patients with metastatic pancreatic cancer. The study will evaluate zoldonrasib combined with chemotherapy against a placebo, focusing on overall survival and progression-free survival. Following the announcement, the company's shares increased, reflecting the positive development in its strategy to deliver targeted therapies for RAS-mutated tumors.
Revolution Medicines Begins Treating Patients in RASolute
Revolution Medicines has started treating patients in its RASolute 305 Phase 3 clinical trial for metastatic RAS G12D pancreatic cancer. The trial evaluates zoldonrasib in combination with chemotherapy as a first-line treatment, building on prior success with daraxonrasib in second-line pancreatic cancer. This effort aims to address the significant unmet medical need in pancreatic cancer, particularly for patients with the aggressive RAS G12D mutation.
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
Revolution Medicines has started treating patients in its RASolute 305 Phase 3 clinical trial, which evaluates zoldonrasib combined with chemotherapy for first-line treatment of metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). This trial aims to improve outcomes for patients with this aggressive cancer, as RAS G12D is the most common and challenging RAS subtype in pancreatic cancer. The company previously reported positive results with another RAS(ON) inhibitor, daraxonrasib, in second-line treatment for pancreatic cancer, supporting the early evaluation of such inhibitors.
